Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. / Kohno, M; Perch, M; Andersen, E; Carlsen, J; Andersen, C B; Iversen, M.

I: Transplantation Proceedings, Bind 43, Nr. 5, 2011, s. 1868-70.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Kohno, M, Perch, M, Andersen, E, Carlsen, J, Andersen, CB & Iversen, M 2011, 'Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation', Transplantation Proceedings, bind 43, nr. 5, s. 1868-70. https://doi.org/10.1016/j.transproceed.2011.02.007

APA

Kohno, M., Perch, M., Andersen, E., Carlsen, J., Andersen, C. B., & Iversen, M. (2011). Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. Transplantation Proceedings, 43(5), 1868-70. https://doi.org/10.1016/j.transproceed.2011.02.007

Vancouver

Kohno M, Perch M, Andersen E, Carlsen J, Andersen CB, Iversen M. Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. Transplantation Proceedings. 2011;43(5):1868-70. https://doi.org/10.1016/j.transproceed.2011.02.007

Author

Kohno, M ; Perch, M ; Andersen, E ; Carlsen, J ; Andersen, C B ; Iversen, M. / Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. I: Transplantation Proceedings. 2011 ; Bind 43, Nr. 5. s. 1868-70.

Bibtex

@article{f1d969402bf3474e87cf4523575557d3,

title = "Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation",

abstract = "A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to a1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.",

author = "M Kohno and M Perch and E Andersen and J Carlsen and Andersen, {C B} and M Iversen",

year = "2011",

doi = "http://dx.doi.org/10.1016/j.transproceed.2011.02.007",

language = "English",

volume = "43",

pages = "1868--70",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier",

number = "5",

}

RIS

TY - JOUR

T1 - Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

AU - Kohno, M

AU - Perch, M

AU - Andersen, E

AU - Carlsen, J

AU - Andersen, C B

AU - Iversen, M

PY - 2011

Y1 - 2011

N2 - A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to a1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.

AB - A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to a1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.

U2 - http://dx.doi.org/10.1016/j.transproceed.2011.02.007

DO - http://dx.doi.org/10.1016/j.transproceed.2011.02.007

M3 - Journal article

VL - 43

SP - 1868

EP - 1870

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -

ID: 40139434